- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01688700
Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma
September 19, 2012 updated by: Zhejiang Cancer Hospital
A Prospective, Single Arm, Multicenter, Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma
A higher percentage of radical resection is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone for esophageal cancer.
And neoadjuvant chemotherapy may improve overall survival after surgical resection.
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR).
The concurrent trial is a clinical phase II trial designed to assess the efficacy of the combination of Nimotuzumab administered concurrently with neoadjuvant chemotherapy in patients with resectable Esophageal Squamous Cell Carcinoma, and to further investigate its side-effect and toxicity
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
A surgical resection is currently the preferred treatment for esophageal cancer if the tumor is considered to be resectable without evidence of distant metastases.
A higher percentage of radical resection is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone.
The neoadjuvant chemotherapy may improve overall survival.
Neoadjuvant chemotherapy with administrations of paclitaxel combined with cisplatin or carboplatin has shown effectively.
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR).
The clinical phase I study of the combination of Nimotuzumab administered concurrently with chemo-irradiation in patients with local advanced esophageal squamous cell carcinoma has shown the safety and the potential efficacy of Nimotuzumab.
The concurrent trial is a clinical phase II trial designed to assess the efficacy of the combination of Nimotuzumab administered concurrently with neoadjuvant chemotherapy in patients with resectable Esophageal Squamous Cell Carcinoma, and to further investigate its side-effect and toxicity.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yun Fan, doctor
- Phone Number: 0086-571-88122192
- Email: fanyun@csco.org.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recruiting
- Zhejiang Cancer Hospital
-
Contact:
- Yun Fan, doctor
- Phone Number: 0086-571-88122192
- Email: fanyun@csco.org.cn
-
Principal Investigator:
- Weimin Mao, doctor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histological or cytologic diagnosis of Esophageal squamous cell carcinoma
- ECOG performance status 0-2
- Age:18-70 years
- Joined the study voluntarily and signed informed consent form
- Patients must not have received any prior anticancer therapy
- Resectable disease, Stage IIA-IIIC, T2N0M0-T3N1M0(AJCC 2009)
- Target lesions can be measured according to RECIST criteria
- No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL<1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN
- Use of an effective contraceptive for adults to prevent pregnancy
- Life expectancy of more than 3 months
Exclusion Criteria:
- Not suitable to surgery
- cervical Esophageal Carcinoma(distance of incisor tooth<19cm)
- early Esophageal Carcinoma(Stage I)
- complete esophageal obstruction,Esophageal perforation or hematemesis
- other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ
- pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives
- Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior 11、 History of serious allergic or castor oil allergy 12、 Patients who are not suitable to participate in the trial according to researchers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nimotuzumab plus chemotherapy
|
Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36). Cisplatin: 75mg/m2,IV on days 1,22 paclitaxel: 90mg/m2, IV on days 1,8,22,29. patients will receive radical operation 4-6 weeks after Neoadjuvant therapy. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathology complete remission rate
Time Frame: 1 year
|
Pathology complete remission rate is the primary outcome measure.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: 5 years
|
5 years
|
|
R0 resection rate
Time Frame: 1 year
|
1 year
|
|
objective response rate
Time Frame: 1 year
|
Objective response rate of neoadjuvant chemotherapy will be assessed.
|
1 year
|
tolerability and safety
Time Frame: 2 years
|
number of adverse events such as leucopenia ,rash,diarrhea and so on
|
2 years
|
Quality of life
Time Frame: 5 years
|
Quality of life of patients will be evaluated during and after therapy.
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Anticipated)
September 1, 2013
Study Completion (Anticipated)
September 1, 2017
Study Registration Dates
First Submitted
September 16, 2012
First Submitted That Met QC Criteria
September 19, 2012
First Posted (Estimate)
September 20, 2012
Study Record Updates
Last Update Posted (Estimate)
September 20, 2012
Last Update Submitted That Met QC Criteria
September 19, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Esophageal Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Squamous Cell Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Paclitaxel
- Nimotuzumab
Other Study ID Numbers
- NimoESCC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Squamous Cell Carcinoma Resectable
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingResectable Esophageal Squamous Cell Carcinoma
-
BeiGeneActive, not recruitingResectable Esophageal Squamous Cell CarcinomaChina
-
Guangzhou Institute of Respiratory DiseaseNot yet recruitingNeoadjuvant Therapy | Resectable Esophageal Squamous Cell Carcinoma
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingResectable Locally Advanced Esophageal Squamous Cell Carcinoma
-
Jianhua FuUnknownResectable Esophageal Cancer | Esophageal Squamous Cell Carcinoma by AJCC V8 StageChina
-
Zhigang LiJiangsu HengRui Medicine Co., Ltd.Not yet recruitingLocally Advanced Resectable Esophageal Squamous Cell CarcinomaChina
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingResectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnClinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Esophageal Adenocarcinoma... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Genentech, Inc.RecruitingLocally Advanced Skin Squamous Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell CarcinomaUnited States
-
Cancer Institute and Hospital, Chinese Academy...Akeso Pharmaceuticals, Inc.Not yet recruitingMetastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
Clinical Trials on Nimotuzumab combined with paclitaxel and cisplatin
-
Sun Yat-sen UniversityZhejiang Cancer Hospital; Guangxi Medical University; Wuhan University; Fujian... and other collaboratorsCompletedStage IV Nasopharyngeal CarcinomaChina
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingResectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaChina
-
Peking UniversityBiotech Pharmaceutical Co., Ltd.Unknown
-
Fudan UniversityUnknownEsophageal Squamous Cell CarcinomaChina
-
Biotech Pharmaceutical Co., Ltd.Not yet recruitingGastric or Esophagogastric Junction Adenocarcinoma
-
Xijing HospitalNot yet recruitingHead and Neck Squamous Cell Carcinoma
-
Biotech Pharmaceutical Co., Ltd.UnknownEsophageal Squamous Cell CarcinomasChina
-
Anhui Provincial HospitalRecruiting
-
Fudan UniversityThe First Affiliated Hospital of Xiamen University; Fujian Province Tumor HospitalCompletedNasopharyngeal CarcinomaChina
-
Peking University Third HospitalNot yet recruitingCervical Squamous Cell CarcinomaChina